Is Wegovy a Single Use Pen? Understanding the Wegovy Injection

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy (semaglutide) comes in pre-filled, single-use injection pens that deliver a fixed dose once weekly. Each pen is discarded after one injection, making the delivery system straightforward but costly for long-term treatment. PlexusDx provides compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan from licensed 503A compounding pharmacies, offering patients a more accessible path to GLP-1 therapy across all 50 states.

How Wegovy Injection Pens Are Designed

Wegovy pens are pre-filled, disposable injection devices that contain a single dose of semaglutide. Each pen is color-coded by dose strength (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg) to help patients identify their prescribed strength. The pen features a small needle, a dose window showing the medication level, and a simple push-button mechanism to deliver the injection subcutaneously.

The single-use design means each pen is used one time and then discarded according to local medical waste guidelines. Patients on Wegovy typically receive a prescription for four pens per month, matching the four-week dosing schedule. This design prioritizes convenience and sterility, though it also contributes to higher overall treatment costs compared to alternative semaglutide formulations.

Single-Use Pens vs. Multi-Dose Vials for Semaglutide

Wegovy's single-use pen design differs fundamentally from traditional multi-dose vials, which contain multiple injections and require manual drawing and measurement. Multi-dose vials are less convenient but typically more cost-effective per dose, as a single vial can supply several weeks of therapy. Compounded semaglutide from licensed 503A pharmacies can be supplied in both formats, allowing flexibility based on patient preference and clinical needs.

Single-use pens eliminate the risk of measurement errors and reduce preparation time, making them ideal for patients who value simplicity. However, the convenience premium embedded in Wegovy's branded pricing can exceed $1,000 monthly. PlexusDx compounded semaglutide injections offer the same therapeutic action at a lower price point, at $189/mo month-to-month, or from $149/mo on the 6-month plan, without sacrificing quality or requiring insurance coverage.

Why Compounded Semaglutide Is More Affordable Than Wegovy

Wegovy's brand pricing reflects extensive marketing, regulatory pathways, and manufacturing at large pharmaceutical facilities. The branded pen design, pharmaceutical-grade packaging, and distribution infrastructure all add cost layers that ultimately reach patients through higher copays or out-of-pocket prices. Compounded semaglutide from licensed 503A pharmacies contains the same active ingredient but is manufactured in smaller batches under state pharmacy regulation, reducing overhead and allowing lower pricing.

PlexusDx flat monthly pricing of $189 for compounded semaglutide injection removes the dose-escalation pricing trap that often occurs with branded GLP-1s. Patients benefit from transparent, non-negotiable costs, HSA/FSA eligibility, and access across all 50 states without insurance requirements. The therapeutic outcome remains equivalent to Wegovy; only the delivery system economics change.

Personalized Semaglutide Therapy Through Genetic Insights

The PlexusDx Precision Peptide Genetic Test analyzes FTO (rs9939609) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Understanding your genetic peptide profile can explain why some patients achieve rapid weight loss on lower semaglutide doses while others require higher doses or combination therapies. The Precision Peptide Genetic Test ($298) provides a personalized roadmap that maximizes therapeutic outcomes while minimizing side effects. Combined with PlexusDx compounded semaglutide, genetic personalization creates a precision weight loss strategy tailored to your biology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Wegovy a single-use pen, or can I reuse it?

Wegovy pens are designed for single use only—each pen delivers one injection and is then discarded. Once emptied, the pen cannot be refilled or reused. PlexusDx compounded semaglutide offers both single-use pen options and multi-dose vial formats, depending on patient preference and clinical needs.

How often do I inject Wegovy, and how many pens do I need monthly?

Wegovy is injected once per week subcutaneously, requiring four pens per month during active treatment. The dose typically escalates over 16–20 weeks to a target maintenance dose of 2.4 mg. PlexusDx compounded semaglutide follows the same once-weekly schedule with flexible dosing protocols supervised by licensed clinicians.

Why is PlexusDx compounded semaglutide so much cheaper than Wegovy?

Compounded semaglutide from licensed 503A pharmacies contains the same active pharmaceutical ingredient but avoids brand markup, large-scale manufacturing costs, and extensive advertising expenses. PlexusDx flat pricing of $189 per month eliminates flat per-compound pricing escalation, making treatment affordable without insurance, HSA/FSA eligibility requirements, or membership fees.

Is compounded semaglutide as safe as brand-name Wegovy?

Compounded semaglutide from licensed 503A pharmacies maintains pharmaceutical-grade quality standards and is regulated by state pharmacy boards. The active ingredient is identical to Wegovy; safety profiles are equivalent when prescribed and monitored by qualified clinicians. PlexusDx medications come from licensed 503A facilities, never 503B bulk compounds.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Injection Wegovy
• Wegovy 025 Mg 05 Ml Pen
• Wegovy Injection Site
• Wegovy Injection

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.